With the same antibody in a non small cell lung cancer (NSCLC) study, at baseline 80% (20/25) of patients had 1–20 CTCs (Cellsearch) and of those 95% (19/20) had some CTCs with detectable PD-L1 ranging from 25–100% of the CTCs [42]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.